Magnus Åstrand

9.1k total citations · 2 hit papers
32 papers, 7.0k citations indexed

About

Magnus Åstrand is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Magnus Åstrand has authored 32 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Surgery, 9 papers in Endocrinology, Diabetes and Metabolism and 7 papers in Molecular Biology. Recurrent topics in Magnus Åstrand's work include Diabetes Treatment and Management (9 papers), Gastroesophageal reflux and treatments (5 papers) and Gene expression and cancer classification (5 papers). Magnus Åstrand is often cited by papers focused on Diabetes Treatment and Management (9 papers), Gastroesophageal reflux and treatments (5 papers) and Gene expression and cancer classification (5 papers). Magnus Åstrand collaborates with scholars based in Sweden, United States and United Kingdom. Magnus Åstrand's co-authors include Terence P. Speed, Rafael A. Irizarry, Benjamin M. Bolstad, Mark Berner Hansen, Lars Ny, Anne Lund Krarup, Magnus Simrén, Peter Funch‐Jensen, Asbjørn Mohr Drewes and Antal Bajor and has published in prestigious journals such as The Lancet, Circulation and Blood.

In The Last Decade

Magnus Åstrand

30 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A comparison of normalization methods for high densityoligonucleotide array data based on variance and bias

2003 6.5k citations Magnus Åstrand et al. profile →
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial

2023 71 citations Hiddo J.L. Heerspink, Arihiro Kiyosue et al. The Lancet profile →

Peers

Countries citing papers authored by Magnus Åstrand

Since Specialization

Citations

This map shows the geographic impact of Magnus Åstrand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Magnus Åstrand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Magnus Åstrand more than expected).

Fields of papers citing papers by Magnus Åstrand

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Magnus Åstrand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Magnus Åstrand. The network helps show where Magnus Åstrand may publish in the future.

Co-authorship network of co-authors of Magnus Åstrand

This figure shows the co-authorship network connecting the top 25 collaborators of Magnus Åstrand. A scholar is included among the top collaborators of Magnus Åstrand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Magnus Åstrand. Magnus Åstrand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	#1003 Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses of AZD2373, an antisense oligonucleotide targeting APOL1 2024 ·Nephrology Dialysis Transplantation ·Peter J. Greasley, Nikhil Agrawal, Magnus Althage, José Sánchez, Sarah Kirk, (unknown), Magnus Åstrand, (unknown), James Sherwood, Michael McCarthy, Uptal D. Patel, Iain MacPhee	1
2	Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo‐Controlled Study 2024 ·Journal of the American Heart Association ·(unknown), Ann‐Charlotte Egnell, Magnus Åstrand, Samuel J. Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen	1
3	Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First‐in‐Human, Randomized, Single‐Blind, Placebo‐Controlled Study 2024 ·Journal of the American Heart Association ·(unknown), Richard T. De George, Sami A. Omar, (unknown), Magnus Åstrand, Magnus Althage, Daniel Pettersen, (unknown), (unknown), João A.C. Lima, (unknown), (unknown), (unknown), Petra Johannesson, Anders Gabrielsen, Marcin Ufnal	4
4	Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease 2024 ·British Journal of Clinical Pharmacology ·Muhammad Waqas Sadiq, (unknown), Magnus Åstrand, Ian C. Scott, Adam Williams, (unknown), N. E. White, (unknown), Monica L. Gavala, E. Suzanne Cohen, (unknown), Chris Kell, Hitesh Pandya, (unknown)	2
5	Population Pharmacokinetic Modeling of Cotadutide: A Dual Agonist Peptide of Glucagon-Like Peptide and Glucagon Receptors Administered to Participants with Type II Diabetes Mellitus, Chronic Kidney Disease, Obesity and Non-Alcoholic Steatohepatitis 2024 ·Clinical Pharmacokinetics ·(unknown), Magnus Åstrand, Jenny Cheng, (unknown), Bengt Hamrén, Anis A. Khan	4
6	Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD 2024 ·Journal of the American Society of Nephrology ·(unknown), (unknown), Neeraj Dhaun, José Luis Górriz, María José Soler, Magnus Åstrand, (unknown), Peter J. Greasley, Phil Ambery, Hiddo J.L. Heerspink	7
7	Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial breakdown → 2023 ·The Lancet ·Hiddo J.L. Heerspink, Arihiro Kiyosue, David C. Wheeler, (unknown), (unknown), Glenn Carlson, (unknown), Magnus Åstrand, Sebastian Ueckert, Peter J. Greasley, Phil Ambery	71
8	Safety, tolerability, and pharmacokinetics of AZD5462, a small molecule agonist of the RXFP1 relaxin receptor 2023 ·European Heart Journal ·Jaya Birgitte Rosenmeier, Katherine Connolly, (unknown), Magnus Åstrand, Magnus Althage, Daniel Pettersen, Alexandra L. Whittaker, Michael Turton, (unknown), A E Gabrielsen	2
9	Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study 2022 ·Blood ·Matthew M. Heeney, Miguel R. Abboud, Jessie Githanga, Baba Inusa, Julie Kanter, Alan D. Michelson, Videlis Nduba, Victor Musiime, (unknown), Adlette Inati, Amar Taksande, Marielle Andersson, Magnus Åstrand, Noha Maklad, Mohammad Niazi, Anders Himmelmänn, Anders Berggren	11
10	Abstract 13097: Safety, Pharmacokinetics, and Pharmacodynamics of AZD3366 Alone and in Combination With Aspirin and Ticagrelor in Healthy Subjects 2022 ·Circulation ·(unknown), Ann‐Charlotte Egnell, Magnus Åstrand, Samuel J. Daniels, (unknown), Carl Whatling, Ola Fjellström, Anders Gabrielsen	1
11	Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease 2021 ·Clinical Pharmacokinetics ·Dinko Rekić, (unknown), Mats Någård, James Chou, (unknown), Charles W. Bradley, Magnus Åstrand, Stacey Tannenbaum, Bengt Hamrén	12
12	Dose-Response Mixed Models for Repeated Measures – a New Method for Assessment of Dose-Response 2020 ·Pharmaceutical Research ·Gustaf J. Wellhagen, Bengt Hamrén, Maria C. Kjellsson, Magnus Åstrand	2
13	Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease 2019 ·Clinical Pharmacokinetics ·(unknown), Mohammad Niazi, Anders Berggren, Magnus Åstrand, Bengt Hamrén	10
14	Activity of neutrophil elastase reflects the progression of acute pancreatitis 2013 ·Scandinavian Journal of Clinical and Laboratory Investigation ·Srdan Novovic, Anders Andersen, Magnus Nord, Magnus Åstrand, (unknown), Lars Nannestad Jørgensen, Mark Berner Hansen	10
15	A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing? 2010 ·Alimentary Pharmacology & Therapeutics ·Philip O. Katz, David A. Johnson, Deborah Levine, Kerstin Röhss, Ola Junghard, Magnus Åstrand, Péter Nagy	8
16	Prevention of Relapse of Healed Reflux Esophagitis is Related to the Duration of Intragastric pH>4 2010 ·Journal of Clinical Gastroenterology ·David A. Johnson, Philip O. Katz, (unknown), Kerstin Röhss, Magnus Åstrand, Ola Junghard, Péter Nagy	8
17	Empirical Bayes models for multiple probe type microarrays at the probe level 2008 ·BMC Bioinformatics ·Magnus Åstrand, Petter Mostad, Mats Rudemo	12
18	Improved Covariance Matrix Estimators for Weighted Analysis of Microarray Data 2007 ·Journal of Computational Biology ·Magnus Åstrand, Petter Mostad, Mats Rudemo	5
19	Contrast Normalization of Oligonucleotide Arrays 2003 ·Journal of Computational Biology ·Magnus Åstrand	45
20	[Decreasing number of orchiectomies in prostatic cancer. Results of 9-year registration of the disease are reviewed]. 1997 ·PubMed ·Gabriel Sandblom, Monika Dufmats, Magnus Åstrand, (unknown), Eberhard Varenhorst	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact